Sanofi pays $315 million to settle Lemtrada go-slow claims

[cafead]

via Sanofi agreed to pay former shareholders of the acquired company Genzyme $315 million to settle claims that the French pharma deliberately slowed development of a multiple sclerosis drug to avoid additional compensation based on regulatory and sales milestones.

article source